Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&A Expertise ReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. Howard Berman, Ph.D., executive chairman, stated: "Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital,
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. ("BIOS" or the "Company") (NASDAQ:BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the "Business Combination Agreement"), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company's initial public offering ("Public Shares"). The Business Combination Agreement was dated as of May 2, 2023. The pa
EATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) ("BIOS") (NASDAQ:BIOS), a special purpose acquisition company, announced today that the two companies have mutually agreed to terminate their proposed business combination. "While we were enthusiastic about the potential business combination with BIOS, we mutually agreed that the current market conditions are not co
15-12G - BioPlus Acquisition Corp. (0001856653) (Filer)
25-NSE - BioPlus Acquisition Corp. (0001856653) (Subject)
RW - BioPlus Acquisition Corp. (0001856653) (Filer)
4 - BioPlus Acquisition Corp. (0001856653) (Issuer)
SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)
SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)
SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)
Company to Welcome New Directors to Board Adam Gray to Serve as Board Chair Gary DiCamillo to Continue to Serve as Lead Independent Director Company Will Redeem Cumulative Voting Proportional Representation Preferred Linked Stock Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple" or the "Company"), a comfort innovation company known for creating the "World's First No Pressure® Mattress," today announced that it has entered into a binding Memorandum of Understanding to establish a cooperative governance framework (the "Planned Cooperation Agreement") with Coliseum Capital Management, LLC (together with its managed funds and accounts, "Coliseum"), the largest stockholder of the Company o